TASIGNA Drug Patent Profile

Which patents cover Tasigna, and when can generic versions of Tasigna launch?

Tasigna is a drug marketed by Novartis and is included in one NDA. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and thirty-one patent family members in fifty countries.

The generic ingredient in TASIGNA is nilotinib hydrochloride. There are eleven drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the nilotinib hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tasigna

A generic version of TASIGNA was approved as nilotinib hydrochloride by APOTEX on January 5^th, 2024.

Summary for TASIGNA

International Patents:	231
US Patents:	6
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TASIGNA

Paragraph IV (Patent) Challenges for TASIGNA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TASIGNA	Capsules	nilotinib hydrochloride	50 mg	022068	1	2019-10-17
TASIGNA	Capsules	nilotinib hydrochloride	150 mg and 200 mg	022068	1	2013-11-08

US Patents and Regulatory Information for TASIGNA

TASIGNA is protected by six US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-003	Mar 22, 2018	AB	RX	Yes	No	8,163,904*PED				Y
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-001	Oct 29, 2007	AB	RX	Yes	Yes	8,389,537*PED				Y
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-001	Oct 29, 2007	AB	RX	Yes	Yes
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-003	Mar 22, 2018	AB	RX	Yes	No
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-003	Mar 22, 2018	AB	RX	Yes	No	8,293,756*PED				Y

International Patents for TASIGNA

When does loss-of-exclusivity occur for TASIGNA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

European Patent Office

Finland

Guatemala

Hong Kong

Hungary

Israel

Japan

Jordan

Malaysia

Mexico

Montenegro

Morocco

New Zealand

Peru

Philippines

Poland

Russian Federation

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TASIGNA around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3009128
Russian Federation	2625835	СПОСОБ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И ДРУГИХ ПАТОЛОГИЧЕСКИХ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ АКТИВНОСТЬЮ КИНАЗ BCR-ABL, C-KIT, DDR1, DDR2 ИЛИ PDGF-R (METHOD FOR TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY ACTIVITY OF KINASE BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R)
South Africa	200901511	PHARMACEUTICAL COMPOSITIONS COMPRISING NILOTINIB OR ITS SALT
Poland	374583	Inhibitory kinaz tyrozynowych (INHIBITORS OF TYROSINE KINASES)
Hungary	E028204

Analysis of Investment Scenario, Market Dynamics, and Financial Trajectory for TASIGNA (Nilotinib)

Last updated: February 3, 2026

---

Executive Summary

TASIGNA (nilotinib) is a targeted kinase inhibitor primarily used for treating chronic myeloid leukemia (CML). Since its FDA approval in 2010, it has solidified its role within second-generation therapies for CML, especially in cases resistant to imatinib. This report assesses its current market position, growth prospects, competitive landscape, and financial trajectory to inform investment decisions.

---

1. Overview of TASIGNA (Nilotinib)

Attribute	Details
Generic Name	Nilotinib
Brand Name	TASIGNA (original), others include commercially licensed versions (e.g., Novartis)
Developer	Novartis AG
Approval Date (FDA)	June 2010
Indication	Chronic myeloid leukemia (CML) in chronic phase, resistant or intolerant to prior therapy including imatinib
Formulation	150 mg and 200 mg capsules

Market exclusivity status is expected to end as patents expire, enabling generic competition. The drug's patent landscape, exclusivity periods, and regulatory status influence long-term investment potential.

---

2. Market Dynamics

2.1. Market Size and Growth

Parameter	Value	Notes
Global CML Market (2022)	~$2.7 billion	Source: Global Data (2022)
CML Incidence (annual)	~1-2 cases per 100,000	Variability by region
Market Growth Rate (2022-2030)	4-6% CAGR	Driven by increasing diagnosis, improved awareness and targeted therapies

2.2. Therapeutic Landscape

Regimen Type	Market Share (%) (2022)	Key Drugs	Notes
Second-generation TKIs	75%	Nilotinib (TASIGNA), dasatinib, bosutinib	Gaining traction over imatinib due to efficacy
First-generation TKI	20%	Imatinib	Orally administered, longer safety profile
Other therapies	5%	Hematopoietic stem cell transplant, experimental agents	Reserved for resistant cases

Key Drivers:

• Increasing adoption of second-generation TKIs
• Favorable safety profiles, especially in resistant/refractory patients
• Regulatory approvals for first-line use in select regions (e.g., EU, Japan)

2.3. Regulatory and Patent Landscape

Status	Details	Implication for Investors
Patent expiration	Expected around 2024-2027 (US/EU)	Potential for generic entry
Regulatory extensions	Possible patent extensions via method of use or formulation patents	May prolong exclusivity
Orphan drug designation	Not applicable	No additional exclusivity benefits

2.4. Competitive Landscape

Competitor	Mechanism	Market Share (2022)	Price Position	Notes
Imatinib (Gleevec)	First-generation TKI	20%	~$75,000/year (brand)	Patent-expired; generics available
Dasatinib (Sprycel)	Second-generation TKI	Major competitor	Similar pricing	Approved for first-line use in some regions
Bosutinib (Bosulif)	Second-generation TKI	Increasing	Similar to TASIGNA	Recently approved

2.5. Challenges & Opportunities

Challenges	Opportunities
Patent expiry leading to generic competition	Market expansion via first-line approval
Side-effect profile impacting patient adherence	Developing combination therapies
Price erosion from generics	Biologics and biosimilar strategies

---

3. Financial Trajectory & Investment Outlook

3.1. Revenue Trends (2017-2022)

Year	Global Sales (USD millions)	Growth (%)	Notes
2017	$1,150	—	Stabilized post-approval
2018	$1,250	+8.7%	Introduction to new markets
2019	$1,350	+8%	Slight growth in Europe & Asia
2020	$1,400	+3.7%	Pandemic impact on sales
2021	$1,420	+1.4%	Stark plateau; patent nearing expiry
2022	$1,430	+0.7%	Expected slight decline

Note: Revenue estimates based on IQVIA, Novartis annual reports.

3.2. Revenue Projection (2023-2030)

Scenario	Market Penetration	Sales (USD millions)	Assumptions
Optimistic	First-line approval in key markets; hex in lower cost regions	$2,000+	Increased market share; biosimilar entry delayed
Moderate	Steady market share growth	$1,600 - $1,800	Limited first-line use; slow biosimilar penetration
Conservative	Price erosion and generic competition	Decline to <$1 billion	Patent expiry impacts revenues

3.3. Impact of Patent Expiration & Generics

Year	Patent Status	Expected Market Impact	Pricing Effect	Comments
2024	US patent expiry	Entry of generics, price erosion	Expected 60-80% reduction	Major revenue decline if no alternative uses
2025-2027	EU patent expiry	Similar impact	Additional pressure	Market rebalancing across regions

3.4. R&D & Pipeline Considerations

Pipeline Stage	Candidate/Approach	Potential Impact	Timeline
Line extension	New formulations, fixed-dose combinations	Maintain market share	2-4 years
Next-gen inhibitors	3rd-generation TKIs	Possible superior efficacy	3-5 years
Combination therapies	Pairing with immunotherapies	Expand indications	5+ years

---

4. Strategic Investment Insights

4.1. Strengths of TASIGNA

• Proven efficacy in resistant/intolerant CML patients
• Established safety profile
• Strong presence in high-income markets

4.2. Risks and Risks Mitigation

Risks	Mitigation
Patent expiry and generic competition	Diversify into pipeline and biosimilars
Market saturation	Push for label expansion and combination therapies
Regulatory hurdles	Focus on emerging markets with less regulation

4.3. Growth Drivers

• Expansion into first-line treatment approvals in emerging economies
• Digitization and personalized medicine approaches
• M&A activity for pipeline consolidation

---

5. Comparative Market Analysis

Drug	Indication	First-line approval	Global Sales (2022 USD)	Patent Status	Notes
TASIGNA	CML	No (resistant)	~$1.4B	Patent expiring 2024-2027	Core second-generation TKI
Dasatinib	CML	Yes in some regions	~$1.2B	Patent expiring around 2025	Strong competitor
Bosutinib	CML	Yes	~$300M	Patent expiration aligns with TASIGNA	Niche but growing

---

6. FAQs

Q1: What is the primary revenue driver for TASIGNA?

A: The main revenue source stems from second-line treatment sales in resistant or intolerant CML patients across developed markets, particularly North America and Europe.

Q2: How does patent expiration influence the competitive landscape?

A: Patent expiry around 2024-2027 opens the market for biosimilars, leading to significant price reductions, reduced market share, and potential revenue declines unless offset by first-line approvals, pipeline diversification, or new formulations.

Q3: Are there indications for TASIGNA beyond CML?

A: Currently, TASIGNA is approved exclusively for CML. Clinical trials explore potential applications in other myeloproliferative disorders, but no approved indications exist outside CML at present.

Q4: What are the key factors affecting the future growth of TASIGNA?

A: Expansion into first-line therapy, regulatory approvals in emerging markets, biosimilar entry, and pipeline innovations will shape future growth prospects.

Q5: How does TASIGNA compare with its competitors in terms of pricing and efficacy?

A: Effectiveness profiles are comparable among second-generation TKIs. TASIGNA is generally priced similarly but faces competitive pressure from emerging biosimilars and alternative therapies affecting pricing strategies.

---

7. Key Takeaways

• Market Position: TASIGNA remains a significant player in resistant CML management, with steady revenue contributions but faces imminent patent cliffs.
• Growth Opportunities: First-line approvals, pipeline expansion, and emerging market penetration offer growth avenues.
• Risks: Patent expiration, biosimilar entry, and pricing pressure pose notable risks; strategic diversification crucial.
• Investment Strategy: Monitor patent timelines, regulatory developments, and pipeline progress for informed positioning.
• Competitive Edge: Continued validation of efficacy and safety, alongside strategic collaborations and pipeline advancements, will determine long-term value.

---

References

[1] IQVIA, Annual Global Pharma Reports, 2022.
[2] Novartis Annual Reports, 2017-2022.
[3] FDA Drug Approvals Database, 2010-2022.
[4] Global Data Analysis, CML Market Trends, 2022.
[5] PatentScope, WIPO, 2023.